Palatin Technologies, Inc.
Index- P/E- EPS (ttm)-3.93 Insider Own11.30% Shs Outstand9.56M Perf Week-26.53%
Market Cap61.75M Forward P/E- EPS next Y-3.81 Insider Trans0.00% Shs Float8.71M Perf Month11.83%
Income-37.40M PEG- EPS next Q-1.20 Inst Own7.90% Short Float1.34% Perf Quarter-16.16%
Sales0.90M P/S68.61 EPS this Y-6.90% Inst Trans- Short Ratio1.29 Perf Half Y-38.95%
Book/sh0.13 P/B47.08 EPS next Y-7.10% ROA-75.20% Target Price43.00 Perf Year-46.39%
Cash/sh2.96 P/C2.07 EPS next 5Y- ROE-134.70% 52W Range4.00 - 24.00 Perf YTD-52.15%
Dividend- P/FCF- EPS past 5Y-15.90% ROI- 52W High-74.58% Beta0.91
Dividend %- Quick Ratio2.10 Sales past 5Y-49.50% Gross Margin80.80% 52W Low52.50% ATR0.85
Employees33 Current Ratio2.10 Sales Q/Q300.00% Oper. Margin- RSI (14)45.29 Volatility12.76% 15.61%
OptionableNo Debt/Eq0.23 EPS Q/Q9.10% Profit Margin- Rel Volume0.89 Prev Close6.12
ShortableYes LT Debt/Eq0.15 EarningsSep 22 BMO Payout- Avg Volume90.40K Price6.10
Recom1.30 SMA20-3.69% SMA50-7.56% SMA200-33.50% Volume9,854 Change-0.33%
Jun-05-15Reiterated Canaccord Genuity Buy $4 → $6
Jan-12-15Reiterated ROTH Capital Buy $6 → $4
May-23-12Initiated Noble Financial Buy
Jan-23-07Initiated Next Generation Buy $5
Sep-22-22 11:00AM
Sep-19-22 04:15PM
Sep-08-22 07:30AM
Sep-02-22 10:28AM
Aug-19-22 07:30AM
Aug-16-22 07:30AM
Jul-26-22 07:30AM
Jul-13-22 10:53AM
May-17-22 08:45AM
May-16-22 07:15AM
May-12-22 08:15AM
May-11-22 09:02AM
May-10-22 08:45AM
May-09-22 05:15PM
May-05-22 06:05PM
May-02-22 01:02PM
Apr-21-22 07:30AM
Apr-13-22 08:24AM
Mar-03-22 07:30AM
Feb-15-22 07:30AM
Feb-14-22 08:15PM
Feb-10-22 05:25PM
Feb-09-22 03:01PM
Feb-08-22 02:38PM
Jan-21-22 07:30AM
Jan-07-22 10:59AM
Dec-29-21 10:18AM
Dec-28-21 07:30AM
Dec-06-21 03:55PM
Nov-30-21 07:30AM
Nov-24-21 11:20AM
Nov-15-21 07:30AM
Nov-10-21 04:30PM
Oct-22-21 07:30AM
Sep-29-21 07:30AM
Sep-27-21 07:30AM
Sep-24-21 07:30AM
Sep-15-21 07:30AM
Sep-13-21 07:00AM
Jul-22-21 05:28PM
Jul-08-21 04:15PM
Jun-29-21 07:30AM
Jun-28-21 07:30AM
Jun-10-21 07:30AM
May-17-21 09:15AM
May-14-21 07:30AM
May-13-21 07:30AM
May-04-21 07:30AM
Apr-20-21 07:30AM
Mar-11-21 08:17AM
Mar-05-21 07:30AM
Feb-17-21 09:15AM
Feb-12-21 07:30AM
Feb-11-21 09:59AM
Feb-10-21 08:01AM
Feb-05-21 09:47AM
Feb-04-21 11:30AM
Dec-22-20 01:17PM
Dec-15-20 07:00AM
Nov-29-20 12:13PM
Nov-19-20 11:11AM
Nov-17-20 09:15AM
Nov-12-20 07:30AM
Sep-28-20 09:00AM
Sep-24-20 04:00PM
Sep-10-20 05:47PM
Aug-13-20 04:12PM
Jul-14-20 01:19PM
Jul-08-20 07:30AM
Jun-29-20 07:30AM
Jun-23-20 04:54PM
Jun-05-20 03:14PM
May-14-20 07:02PM
May-13-20 03:01AM
May-12-20 07:30AM
Apr-30-20 07:30AM
Mar-28-20 10:28AM
Mar-03-20 12:56PM
Feb-21-20 10:22AM
Feb-19-20 07:30AM
Feb-11-20 07:30AM
Feb-06-20 07:30AM
Jan-21-20 07:30AM
Jan-16-20 08:36AM
Dec-20-19 05:13PM
Dec-11-19 11:43AM
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.